未经证实:从基于人群的研究中发现与Stevens-Johnson综合征(SJS)和中毒性表皮坏死松解症(TEN)相关因素的证据很少。
未经评估:我们旨在确定发病率,危险因素,以及在一般人群中引发SJS/TEN发展的药物。
UNASSIGNED:一个地区,以人口为基础,从2012年至2020年,使用静冈Kokuho数据库对2,398,393名日本人的纵向队列进行了分析.
未经授权:在1,909,570人中,223(0.01%,2.3例/100,000人年)的患者在最长7.5年的观察期内被诊断为SJS/TEN。在多变量分析中,SJS/TEN的风险是年龄较大,和2型糖尿病的存在,外周血管疾病,和全身性自身免疫性疾病。药物的管理,如免疫检查点抑制剂,胰岛素,和2型糖尿病药物,触发了SJS/TEN的发作。
未经评估:结果可能仅适用于日本人口。
未经评估:在代表一般人群的数据库中,发生SJS/TEN的风险是老年和2型糖尿病史,外周血管疾病,和全身性自身免疫性疾病。此外,除了以前报道的药物,免疫检查点抑制剂的施用,胰岛素,和2型糖尿病药物,可能会触发SJS/TEN的开发。
UNASSIGNED: Evidence of factors associated with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) from population-based studies is scarce.
UNASSIGNED: We aimed to identify the incidence, risk factors, and drugs that trigger the development of SJS/TEN in the general population.
UNASSIGNED: A regional, population-based, longitudinal cohort with 2,398,393 Japanese individuals was analyzed using the Shizuoka Kokuho Database from 2012 to 2020.
UNASSIGNED: Among 1,909,570 individuals, 223 (0.01%, 2.3 cases/100,000 person-years) patients were diagnosed with SJS/TEN during the observational period of a maximum of 7.5 years. In a multivariable analysis, the risks of SJS/TEN were an older age, and the presence of type 2 diabetes, peripheral vascular disease, and systemic autoimmune diseases. The administration of drugs, such as immune checkpoint inhibitors, insulin, and type 2 diabetes agents, triggered the onset of SJS/TEN.
UNASSIGNED: The results may apply only to the Japanese population.
UNASSIGNED: In this cohort population from a database representing the general population, the risks of developing SJS/TEN were old age and a history of type 2 diabetes, peripheral vascular disease, and systemic autoimmune disease. Furthermore, in addition to previously reported drugs, the administration of immune checkpoint inhibitors, insulin, and type 2 diabetes agents, may trigger the development of SJS/TEN.